VAD REGIMEN AS INITIAL TREATMENT FOR MULTIPLE MYELOMA

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

MASHHADI MOHAMMAD ALI; HASHEMI MEHDI; KHOSRAVI NEGIN

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: International Journal of Hematology-Oncology and Stem Cell Research Year:2010 | Volume:4 | Issue:4 Page(s): 22-24

Download Full-Text

View:

329

Download:

Cites:

Information Journal Paper

Title

VAD REGIMEN AS INITIAL TREATMENT FOR MULTIPLE MYELOMA

Author(s)

MASHHADI MOHAMMAD ALI | HASHEMI MEHDI | KHOSRAVI NEGIN

Keywords

VAD REGIMEN

INITIAL THERAPY

MULTIPLE MYELOMA

Abstract

Introduction: The aim of our study is evaluation of response rate of VAD (Vincristin, Adriamycin and Dexamethason) regimen as initial treatment in 40 new cases of MULTIPLE MYELOMA. This is the first systemic and classic report of VAD REGIMEN in Iranian population.Methods: All patients with at least stage 2 MULTIPLE MYELOMA or progressive disease after physical examination, para-clinical profile such as (Imaging, CBC, BUN, Creatinine, Ca, P, Alk Phos, protein eletrophoresis, immuno electrophoresis and B 2 Microglobuline) entered to this study and investigation. All patients received VAD REGIMEN (Vincristin 0.4mg/day 1®4 days, Adriamycin 9mg/m2 1®4 days and Dexamethasone 40 mg/day/1®4 (days), 9®12 (days), 17®20 (days) /cycle in outpatient therapy (24mg/morning and 16 mg evening) and repeated every 28 days for 4 cycles. The evaluation of response rate was with: decreased clinical manifestation, changes in para clinical profile and M- component and B 2 microglubuline.Results: Fourty (40) patients enrolled, 24 cases (60%) were female, 16 (40%) male, the mean age was 48 (25 64), IgG myeloma was 80% (32), IgA myeloma 15% (6), and IgM myeloma 5% (2).9 cases had thrombocytopenia in initiation of treatment and 7 cases during treatment protocol, and in the end of treatment, thrombocytopenia remained in 3 cases (total 16 cases) with mild thrombocytopenia (PLT=100, 000-120, 000), azotemia detected in 7 cases and in 2 cases resolved during treatment protocol. The over all response rate was 85%, median survival to now was 44.3 months. Toxicity was mild and acceptable.Conclusion: Our result revealed the high response rate of VAD REGIMEN as INITIAL THERAPY and good survival rate with minor and acceptable toxicity.

Multimedia

No record.

Cites

No record.

References

No record.

Cite

APA: Copy

MASHHADI, MOHAMMAD ALI, HASHEMI, MEHDI, & KHOSRAVI, NEGIN. (2010). VAD REGIMEN AS INITIAL TREATMENT FOR MULTIPLE MYELOMA. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR), 4(4), 22-24. SID. https://sid.ir/paper/313340/en

Vancouver: Copy

MASHHADI MOHAMMAD ALI, HASHEMI MEHDI, KHOSRAVI NEGIN. VAD REGIMEN AS INITIAL TREATMENT FOR MULTIPLE MYELOMA. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR)[Internet]. 2010;4(4):22-24. Available from: https://sid.ir/paper/313340/en

IEEE: Copy

MOHAMMAD ALI MASHHADI, MEHDI HASHEMI, and NEGIN KHOSRAVI, “VAD REGIMEN AS INITIAL TREATMENT FOR MULTIPLE MYELOMA,” INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR), vol. 4, no. 4, pp. 22–24, 2010, [Online]. Available: https://sid.ir/paper/313340/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops